Originally developed to help manage blood sugar levels in type 2 diabetes and obesity, Ozempic is an FDA-approved prescription medication that contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist
In addition to Mehta and Alexander, the study was co-authored by Xuya Xiao, Sophie Dilek, Sydney Lewis, Qilin Deng, Minji Kim, Dami Bolanle, and Ian Saldanha
However, in these trials, the drug was not proven effective at significantly reducing weight of the obese individuals, supported by robust statistical analysis.
If this reaction slows down due to a lack of active B12, as a result of glutathione deficiency, it affects both these cycles
In patients with T2D, chronic hyperglycaemia, as evidenced by high HbA1c levels, is strongly related to the risk of cardiovascular disease (CVD) and death by inducing oxidative stress and inflammation and promoting atherosclerosis and endothelial dysfunction